230 related articles for article (PubMed ID: 37564178)
1. Targeting copper metabolism: a promising strategy for cancer treatment.
Kong R; Sun G
Front Pharmacol; 2023; 14():1203447. PubMed ID: 37564178
[TBL] [Abstract][Full Text] [Related]
2. The potential value of cuprotosis (copper-induced cell death) in the therapy of clear cell renal cell carcinoma.
Qi X; Wang J; Che X; Li Q; Li X; Wang Q; Wu G
Am J Cancer Res; 2022; 12(8):3947-3966. PubMed ID: 36119838
[TBL] [Abstract][Full Text] [Related]
3. Targeting cuproplasia and cuproptosis in cancer.
Tang D; Kroemer G; Kang R
Nat Rev Clin Oncol; 2024 May; 21(5):370-388. PubMed ID: 38486054
[TBL] [Abstract][Full Text] [Related]
4. A new thinking: deciphering the aberrance and clinical implication of copper-death signatures in clear cell renal cell carcinoma.
Jiang A; Luo P; Chen M; Fang Y; Liu B; Wu Z; Qu L; Wang A; Wang L; Cai C
Cell Biosci; 2022 Dec; 12(1):209. PubMed ID: 36581992
[TBL] [Abstract][Full Text] [Related]
5. Cope with copper: From copper linked mechanisms to copper-based clinical cancer therapies.
Wang X; Zhou M; Liu Y; Si Z
Cancer Lett; 2023 May; 561():216157. PubMed ID: 37011869
[TBL] [Abstract][Full Text] [Related]
6. Cuproptosis: Harnessing Transition Metal for Cancer Therapy.
Wang W; Mo W; Hang Z; Huang Y; Yi H; Sun Z; Lei A
ACS Nano; 2023 Oct; 17(20):19581-19599. PubMed ID: 37820312
[TBL] [Abstract][Full Text] [Related]
7. A novel network-based method identifies a cuproplasia-related pan-cancer gene signature to predict patient outcome.
Pham VVH; Jue TR; Bell JL; Luciani F; Michniewicz F; Cirillo G; Vahdat L; Mayoh C; Vittorio O
Hum Genet; 2024 Apr; ():. PubMed ID: 38642129
[TBL] [Abstract][Full Text] [Related]
8. Integrative analysis revealed that distinct cuprotosis patterns reshaped tumor microenvironment and responses to immunotherapy of colorectal cancer.
Xu X; Ding C; Zhong H; Qin W; Shu D; Yu M; Abuduaini N; Zhang S; Yang X; Feng B
Front Immunol; 2023; 14():1165101. PubMed ID: 37006250
[TBL] [Abstract][Full Text] [Related]
9. Regulatory roles of copper metabolism and cuproptosis in human cancers.
Wang Z; Jin D; Zhou S; Dong N; Ji Y; An P; Wang J; Luo Y; Luo J
Front Oncol; 2023; 13():1123420. PubMed ID: 37035162
[TBL] [Abstract][Full Text] [Related]
10. Copper homeostasis and cuproptosis in gynecological disorders: Pathogenic insights and therapeutic implications.
Lin Y; Yuan M; Wang G
J Trace Elem Med Biol; 2024 Jul; 84():127436. PubMed ID: 38547725
[TBL] [Abstract][Full Text] [Related]
11. Is copper chelation an effective anti-angiogenic strategy for cancer treatment?
Antoniades V; Sioga A; Dietrich EM; Meditskou S; Ekonomou L; Antoniades K
Med Hypotheses; 2013 Dec; 81(6):1159-63. PubMed ID: 24210000
[TBL] [Abstract][Full Text] [Related]
12. A Novel Cuprotosis-Related lncRNA Signature Effectively Predicts Prognosis in Glioma Patients.
Wu S; Ballah AK; Che W; Wang X
J Mol Neurosci; 2023 Mar; 73(2-3):185-204. PubMed ID: 36705778
[TBL] [Abstract][Full Text] [Related]
13. Identification of cuprotosis-mediated subtypes, the development of a prognosis model, and influence immune microenvironment in hepatocellular carcinoma.
Xiao J; Liu Z; Wang J; Zhang S; Zhang Y
Front Oncol; 2022; 12():941211. PubMed ID: 36110946
[TBL] [Abstract][Full Text] [Related]
14. FDX1 inhibits thyroid cancer malignant progression by inducing cuprotosis.
Chen G; Zhang J; Teng W; Luo Y; Ji X
Heliyon; 2023 Aug; 9(8):e18655. PubMed ID: 37554785
[TBL] [Abstract][Full Text] [Related]
15. Cuprotosis Programmed-Cell-Death-Related lncRNA Signature Predicts Prognosis and Immune Landscape in PAAD Patients.
Chi H; Peng G; Wang R; Yang F; Xie X; Zhang J; Xu K; Gu T; Yang X; Tian G
Cells; 2022 Oct; 11(21):. PubMed ID: 36359832
[TBL] [Abstract][Full Text] [Related]
16. Cuprotosis-related signature predicts overall survival in clear cell renal cell carcinoma.
Zhang F; Lin J; Feng D; Liang J; Lu Y; Liu Z; Wang X
Front Cell Dev Biol; 2022; 10():922995. PubMed ID: 36247012
[No Abstract] [Full Text] [Related]
17. Systematic analysis of the cuprotosis in tumor microenvironment and prognosis of gastric cancer.
Wang KW; Wang MD; Li ZX; Hu BS; Huang JF; Wu JJ; Yuan ZD; Wu XL; Yuan QF; Sun YF; Yuan FL
Heliyon; 2023 Mar; 9(3):e13831. PubMed ID: 36895378
[TBL] [Abstract][Full Text] [Related]
18. Cuprotosis Patterns Are Associated with Tumor Mutation Burden and Immune Landscape in Lung Adenocarcinoma.
Liu T; Cai L; Hua H; Jiang X; Xu X; Zhang T; Huang W; Qian L; Bai H; Duan J
J Oncol; 2022; 2022():9772208. PubMed ID: 36467497
[TBL] [Abstract][Full Text] [Related]
19. Construction and Validation of a risk model Based on Cuprotosis-related LncRNAsin Colon Adenocarcinoma.
Tan P; Hao R; Zhu Q; Wu X; Zhang Y
Cell Mol Biol (Noisy-le-grand); 2022 Dec; 68(12):84-90. PubMed ID: 37130175
[TBL] [Abstract][Full Text] [Related]
20. Machine learning-based characterization of cuprotosis-related biomarkers and immune infiltration in Parkinson's disease.
Zhao S; Zhang L; Ji W; Shi Y; Lai G; Chi H; Huang W; Cheng C
Front Genet; 2022; 13():1010361. PubMed ID: 36338988
[No Abstract] [Full Text] [Related]
[Next] [New Search]
